The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > TRENDS
TRENDS
-
Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
-
Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
-
As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
-
Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
-
AGs Set to Break into 10 Billion Yen Territory in Japan
November 14, 2016
-
Gilead Stays Pat on Hep C Plan, Japan Chief Says Innovation Outstrips Re-Pricing Hit
October 18, 2016
-
Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
September 26, 2016
-
Sumitomo Dainippon Feeling Sense of Crisis about Operating Profit to Approach Zero; Will Offer Early Retirement and Cut Executive Compensation
September 15, 2016
-
Surprise Rule Change Pops Up Yet Again, This Time with Taltz
September 5, 2016
-
Top Global Pharmas Lackluster in Japan while Hep C Drug Makers Flourish
June 21, 2016
-
Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020
April 13, 2016
-
Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
-
Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
-
Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
-
Takeda’s Exit from Diabetes Research a Symbolic Move under Weber Leadership
January 20, 2016
-
Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…